Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients
NCT02323139Phase 1Completed
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- Feb 2015
- Primary completion
- Jan 2018
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sonidegib in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML), sponsored by Groupe Français des Myélodysplasies. Primary endpoint: Safety of the combination assessed by evaluation of hematological and non-hematological toxicities at 1 month. Started Feb 2015; status: completed.
02
Drugs
sonidegib
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT02323139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02323139.